versus 0.698 (standard care). From age 12, HRQoL INNOVATE≥3 INNOVATE≥3 difference as adults exacerbations exacerbations INNOVATE: 0.787 and adolescents. () () vs. 0.651 loss due CSNS = -0.10 Lloyd et al CSNS = -0.10 et al to CSS = -0.20 (2007) () CSS = -0.20 (2007) () exacerbations Duration of Lloyd et al Lloyd et al 4 weeks 4 exacerbation (2007) () (2007) () Resource use and INNOVATE () IA-05 EUP () NHS Reference NHS Reference Cost of CSNS = £154.70 costs () CSNS=CSS=£213.89 costs () exacerbations CSS = £178.87 PSSRU Unit PSSRU Unit costs () costs () 2 per year, £160 2 per year, £190 Routine visits each NHS reference each NHS reference Initiation of costs () () £245 £247 therapy Standard therapy £1,197 INNOVATE () £810 IA-05 EUP () (per year) Omalizumab costs £8,056 INNOVATE () £8,455 IA-05 EUP () (per year) Administration INNOVATE () IA-05 EUP () and First year: £260 year: £268 NHS reference NHS reference monitoring Thereafter: £146 Thereafter: £151 costs () costs () costs
versus 0.698 (standard care). INNOVATE: 0.787 vs. 0.651 INNOVATE≥3 exacerbations () From age 12, HRQoL difference as adults and adolescents. INNOVATE≥3 exacerbations () loss due to exacerbations CSNS = -0.10 CSS = -0.20 Lloyd et al (2007) () CSNS = -0.10 CSS = -0.20 et al (2007) () Duration of exacerbation 4 weeks Lloyd et al (2007) () 4 Lloyd et al (2007) () Resource use and Cost of exacerbations CSNS = £154.70 CSS = £178.87 INNOVATE () NHS Reference costs () PSSRU Unit costs () CSNS=CSS=£213.89 IA-05 EUP () NHS Reference costs () PSSRU Unit costs () Routine visits 2 per year, £160 each NHS reference costs () 2 per year, £190 each NHS reference () Initiation of therapy £245 £247 Standard therapy (per year) £1,197 INNOVATE () £810 IA-05 EUP () Omalizumab costs (per year) £8,056 INNOVATE () £8,455 IA-05 EUP () Administration and monitoring costs First year: £260 Thereafter: £146 INNOVATE () NHS reference costs () year: £268 Thereafter: £151 IA-05 EUP () NHS reference costs ()